Xianju Pharmaceutical announced that the company recently received an acceptance notice from the State Drug Administration regarding the registration of drugs produced in the domestic production of betahistine mesylate tablets. The specification of this drug is 6 mg. The reference preparation is a drug originally developed and marketed by Eisai Pharmaceutical Co., Ltd. The indications include vertigo associated with Meniere's disease and Meniere's syndrome.

Zhitongcaijing · 10/16 08:49
Xianju Pharmaceutical announced that the company recently received an acceptance notice from the State Drug Administration regarding the registration of drugs produced in the domestic production of betahistine mesylate tablets. The specification of this drug is 6 mg. The reference preparation is a drug originally developed and marketed by Eisai Pharmaceutical Co., Ltd. The indications include vertigo associated with Meniere's disease and Meniere's syndrome.